Provectus Begins Phase II Psoriasis Trial

Provectus Pharmaceuticals will begin Phase II testing of PH-10, a topical treatment for psoriasis.

The study will evaluate the efficacy of PH-10 in 25 subjects with moderate to severe forms of the disease.

The drug will be applied twice weekly for up to 12 weeks to psoriatic plaque areas. Response will be graded using the Psoriasis Severity Index and an investigator’s clinical assessment of plaque response, Provectus said.